esk-001
Small moleculeexperimental
Clinical trial activity
11 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
7
Phase 3
3
Phase 4
0
Earliest trial started Mar 17, 2022 (NCT05330858)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06962774 | Phase 1 | May 9, 2025 | Alumis Inc |
| NCT06952634 | Phase 1 | Apr 29, 2025 | Alumis Inc |
| NCT06846541 | Phase 3 | Jan 8, 2025 | Alumis Inc |
| NCT06588738 | Phase 3 | Aug 20, 2024 | Alumis Inc |
| NCT06586112 | Phase 3 | Jul 25, 2024 | Alumis Inc |
| NCT05966480 | Phase 2 | Jun 26, 2023 | Alumis Inc |
| NCT05953688 | Phase 2 | Jun 14, 2023 | Alumis Inc |
| NCT05739435 | Phase 2 | Jan 17, 2023 | Alumis Inc |
| NCT05600036 | Phase 2 | Sep 27, 2022 | Alumis Inc |
| NCT05431634 | Phase 1 | May 12, 2022 | Alumis Inc |
| NCT05330858 | Phase 1 | Mar 17, 2022 | Alumis Inc |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alumis Inc | For profit | 11 | 11 | 3 | 2022 |
1 organizations
Page 1 / 1